Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (Q85001070)
Jump to navigation
Jump to search
scientific article published on 01 March 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs |
scientific article published on 01 March 2012 |
Statements
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (English)
Roy Fleischmann
Maurizio Cutolo
Mark C Genovese
Eun Bong Lee
Keith S Kanik
Seth Sadis
Carol A Connell
David Gruben
Sriram Krishnaswami
Gene Wallenstein
Bethanie E Wilkinson
Samuel H Zwillich
1 March 2012